Concurrent onabotulinumtoxina treatment of cervical dystonia and concomitant migraine
Headache: The Journal of Head and Face Pain,  Clinical Article

Winner PK et al. – Concurrent treatment with onabotulinumtoxinA is effective and well tolerated in controlling the symptoms of cervical dystonia complicated by concurrent migraine.

Methods
  • An open–label pilot study was conducted for 7.5 months in patients at least 18 years old with primary cervical dystonia of moderate severity (baseline rating of at least 20 on the Toronto Western Spasmodic Torticollis Rating Scale) complicated by migraine headache meeting the International Classification of Headache Disorders–II criteria for migraines with or without aura.
  • Each patient received 2 cycles of treatment at Visit 3 (baseline) and Visit 6 (Day 90).
  • For cervical dystonia, each patient was injected with a maximum of 175 units.
  • At the same visit, a maximum of 125 units was also injected for migraine using a fixed–site, fixed–dose injection paradigm, with additional cervical dystonia injection–site treatment to a maximum dose of 300 units.
  • Patients were assessed following onabotulinumtoxinA injection and at follow–up on Visit 4 (Day 30), Visit 5 (Day 60), Visit 6 (Day 90), and at Visits 7, 8, and 9 (Days 120, 150, and 180).
  • The primary outcome measures for this study were change in Toronto Western Spasmodic Torticollis Rating Scale total score for cervical dystonia and frequency of headache episodes per 28–day period.
  • Migraine episodes were defined as at least 4 hours of sustained pain with no upper limit.
  • An episode was considered new if the patient was pain free for at least 24 hours.
  • Secondary study end points included number of headache days per month, headache intensity, headache disability (assessed using Headache Impact Test–6 and the Migraine Disability Assessment score scales), acute headache medication use, resource utilization, and allodynia pain.
  • Adverse events were reported.

Results
  • A total of 25 patients (24 women, mean age 50.5 years; mean age of disease onset 21.9 years) were enrolled in the study.
  • Patients experienced improvement in cervical dystonia symptoms with significant reductions from baseline in Toronto Western Spasmodic Torticollis Rating Scale scores at 30, 60, 90, 120, 150, and 180 days (–9.84 ± 8.49, –12.67 ± 8.22, –13.63 ± 7.27, –14.92 ± 7.05, –4.76 ± 6.97, –14.49 ± 6.14, respectively, P < .0001 at all time points from a baseline of 31.03 ± 3.61).
  • Changes from baseline were assessed using the t–test.
  • Reductions in the number of headache episodes from baseline on concurrent onabotulinumtoxinA treatment for coexistent chronic migraine did not attain significance.
  • However, patients experienced significant reductions from baseline in the number of headache days at 90, 120, and 180 days (–3.39 ± 6.78, P = .0289; –4.29 ± 7.94, P = .0194; –4.38 ± 7.99, P = .0178, respectively, from a baseline of 15.33 ± 6.76).
  • Changes from baseline were assessed using the t–test.
  • The change from baseline in Headache Impact Test–6 total scores was significant at 30, 60, 90, 150, and 180 days (3.21 ± 4.14, P = .0009; –3.04 ± 4.04, P = .0012; –2.41 ± 2.79, P = .0006; –2.59 ± 3.87, P = .0050; –3.09 ± 3.80, respectively, from a baseline of 22.68 ± 3.20).
  • Changes from baseline were assessed using the t–test.
  • The change from baseline in Migraine Disability Assessment was significant at 120, 150, and 180 days (–38.09 ± 47.87, P < .0001, Wilcoxon signed rank test; –16.91 ± 62.69, P = .0358, Wilcoxon signed rank test; ?23.73 ± 40.57, P = .0122, t–test, respectively, from a baseline of 56.68 ± 50.41).
  • There were no serious adverse events or treatment–related disc

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Neurology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Neurology Articles

1 Zolpidem and the risk of Parkinson's disease: A nationwide population-based study Journal of Psychiatric Research, August 1, 2014    Clinical Article

2 Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial The Lancet, October 17, 2014    Evidence Based Medicine    Clinical Article
Exclusive Author Commentary

3 Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: A multi-stage, randomised, double-blind, placebo-controlled trial The Lancet Neurology, October 9, 2014    Clinical Article

4 Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial Cerebrovascular Diseases, October 16, 2014    Clinical Article

5 Dairy products and the risk of stroke and coronary heart disease: the Rotterdam Study European Journal of Nutrition, October 14, 2014    Clinical Article

6 Hyperhomocysteinemia and risk of cognitive decline: a meta-analysis of prospective cohort studies European Neurology, October 17, 2014    Review Article

7 Intracranial hemorrhage risk with the new oral anticoagulants: A systematic review and meta-analysis Journal of Neurology, September 2, 2014    Evidence Based Medicine    Review Article

8 Patent foramen ovale closure versus medical therapy for stroke prevention: meta analysis of randomized trials and review of heterogeneity in meta analyses Canadian Journal of Cardiology, August 7, 2014    Evidence Based Medicine    Review Article    Clinical Article

9 Consumption of nuts and legumes and risk of stroke: a meta-analysis of prospective cohort studies Nutrition, Metabolism & Cardiovascular Diseases, July 28, 2014    Evidence Based Medicine    Clinical Article

10 Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial The Lancet Neurology, October 27, 2014    Evidence Based Medicine    Clinical Article

11 Antiepileptics in migraine prophylaxis: An updated Cochrane review Cephalalgia, August 14, 2014    Clinical Article

12 The durability of endovascular coiling versus neurosurgical clipping of ruptured cerebral aneurysms: 18 year follow-up of the UK cohort of the International Subarachnoid Aneurysm Trial (ISAT) The Lancet, October 30, 2014    Evidence Based Medicine    Clinical Article

13 Circulating biomarkers of dairy fat and risk of incident stroke in US men and women in 2 large prospective cohorts American Journal of Clinical Nutrition, October 1, 2014    Clinical Article

14 Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: A nationwide cohort study American Journal of Medicine, September 29, 2014    Clinical Article

15 Antiplatelet strategies for secondary prevention of stroke and TIA Current Atherosclerosis Reports, September 11, 2014    Review Article

16 Management of high-grade gliomas in the elderly Seminars in Radiation Oncology, October 6, 2014    Clinical Article

17 Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial European Heart Journal, September 17, 2014    Clinical Article

18 Long-term outcomes after combined revascularization surgery in adult moyamoya disease Stroke, October 8, 2014    Evidence Based Medicine    Clinical Article

19 Oral anticoagulants for stroke prevention in atrial fibrillation Current Problems in Cardiology, September 23, 2014    Review Article

20 Potassium intake and risk of stroke in women with hypertension and nonhypertension in the women’s health initiative Stroke, September 24, 2014    Clinical Article

Indexed Journals in Neurology: Current Opinion in Neurology, Stroke, Seizure, Cephalgia, Brain Injurymore